• 1
    Pangborn MC: Isolation and purification of a serologically active phospholipid from beef heart. J Biol Chem 143: 247256, 1942
  • 2
    Moore JE, Lutz WB: The natural history of systemic lupus erythematosus: an approach to its study through chronic biologic false positive reactors. J Chronic Dis 1: 297316, 1955
  • 3
    Conley CL, Hartmann RC: A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 31: 621622, 1952
  • 4
    Laurell A-B, Nilsson IM: Hypergammaglobulinemia, circulating anticoagulant, and biologic false positive Wassermann reaction. J Lab Clin Med 49: 694707, 1957
  • 5
    Margolius A Jr, Jackson DP, Ratnoff OD: Circulating anticoagulants: a study of 40 cases and a review of the literature. Medicine (Baltimore) 40: 145202, 1961
  • 6
    Feinstein DI, Rapaport SI: Acquired inhibitors of blood coagulation. Prog Hemostas Thromb 1: 7595, 1972
  • 7
    Clyne L: Species specificity of lupus-like anticoagulant. Blut 53: 287292, 1986
  • 8
    Rapaport SI, Ames SB, Duvall BJ: A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with antiprothrombinase activity. Blood 15: 212227, 1960
  • 9
    Yin ET, Gaston LW: Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus. Thromb Haemost 14: 89115, 1965
  • 10
    Loeliger A: Prothrombin as co-factor of the circulating anticoagulant in systemic lupus erythematosus? Thromb Haemost 3: 237256, 1959
  • 11
    Hughes GRV: Thrombosis, abortion, cerebral disease and the lupus anticoagulant. BMJ 287: 10881089, 1983
  • 12
    Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN: Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol 62: 738745, 1985
  • 13
    Johansson AE, Lassus A: The occurrences of circulating anticoagulants in patients with syphilitic and biologically false positive antilipoidal antibodies. Ann Clin Res 6: 105108, 1974
  • 14
    McNeil HP, Chesterman CN, Krilis SA: Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 49: 193280, 1991
  • 15
    Harris EN, Gharavi AE, Tincani A, Chan JKH, Englert H, Mantelli P, Allegro F, Ballestrieri G, Hughes GRV: Affinity purified anti-cardiolipin and anti-DNA antibodies. J Clin Lab Immunol 17: 155162, 1985
  • 16
    Exner T, Sahman N, Trudinger B: Separation of anticardiolipin antibodies from lupus anticoagulant on a phospholipid-coated polystyrene column. Biochem Biophys Res Commun 155: 10011007, 1988
  • 17
    Galli M, Cornfurius P, Maassen C, Hemker HC, De Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM: Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor. Lancet 335: 15441547, 1990
  • 18
    McNeil HP, Simpson RJ, Chesterman CN, Krilis SA: Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 87: 41204124, 1990
  • 19
    Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T: Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 336: 177178, 1990
  • 20
    Lozier J, Takahashi N, Putnam FW: Complete amino acid sequence of human plasma β2-glycoprotein I. Proc Natl Acad Sci U S A 81: 36403644, 1984
  • 21
    Steinkasserer A, Estaller C, Weiss EH, Sim RB, Day AJ: Complete nucleotide and amino acid sequence of human beta-2-glycoprotein I. Biochem J 277: 387391, 1991
  • 22
    Matsuura E, Igarashi M, Igarashi Y, Nagae H, Ichikawa K, Yasuda T, Koike T: Molecular definition of human β2-glycoprotein I (β2GPI) by cDNA cloning and inter-species differences of β2GPI in alteration of anticardiolipin binding. Int Immunol 3: 12171221, 1991
  • 23
    Reid KBM, Bentley DR, Campbell RD, Chung LP, Sim RB, Kristensen T, Tack BF: Complement system proteins which interact with C3b or C4b: a superfamily of structurally related proteins. Immunol Today 7: 230234, 1986
  • 24
    Polz E, Wurm H, Kostner GM: Investigations on β2-glycoprotein-I in the rat: isolation from serum and demonstration in lipoprotein density fractions. J Biochem 11: 265270, 1980
  • 25
    Wurm H: β2-glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem 16: 511515, 1984
  • 26
    Hunt J, Krilis S: The fifth domain of β2-glycoprotein I contains a phospholipid binding site (cys281-cys288), and a region recognised by anticardiolipin antibodies. J Immunol 152: 653659, 1994
  • 27
    Kertesz Z, Yu B, Steinkasserer A, Haupt H, Benham A, Sim RB: Characterization of binding of human β2-glycoprotein I to cardiolipin. Biochem J 310: 315321, 1995
  • 28
    Nimpf J, Bevers EM, Bomans PHH, Till U, Wurm H, Kostner GM, Zwaal RFA: Prothrombinase activity of human platelets is inhibited by β2-glycoprotein I. Biochim Biophys Acta 884: 142149, 1986
  • 29
    Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM: Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 68: 297300, 1992
  • 30
    Roubey RAS, Pratt CW, Buyon JP, Winfield JB: Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon β2-glycoprotein I. J Clin Invest 90: 11001104, 1992
  • 31
    Schousboe I: β2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 66: 10861091, 1985
  • 32
    Nimpf J, Wurm H, Kostner GM: β2-glycoprotein-I (apo H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 63: 109114, 1987
  • 33
    Shi W, Chong BH, Hogg PJ, Chesterman CN: Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost 70: 342345, 1993
  • 34
    Bancsi LFJMM, van der Linden IK, Bertina RM: β2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 67: 649653, 1992
  • 35
    Roubey RAS, Harper MF, Lentz BR: The interaction of β2-glycoprotein I with phospholipid membranes (abstract). Arthritis Rheum 38 (Suppl 9): S211, 1995
  • 36
    Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Suzuki T, Sumida T, Yasuda T, Koike T: Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 148: 38853891, 1992
  • 37
    Matsuura E, Igarashi Y, Yasuda T, Koike T, Triplett DA: Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 179: 457462, 1994
  • 38
    Roubey RAS, Eisenberg RA, Harper MF, Winfield JB: “Anticardiolipin” autoantibodies recognize β2-glycoprotein I in the absence of phospholipid: importance of antigen density and bivalent binding. J Immunol 154: 954960, 1995
  • 39
    Pengo V, Biasiolo A, Fior MG: Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-glycoprotein I is bound to a suitable surface. Thromb Haemost 73: 2934, 1995
  • 40
    Arvieux J, Roussel B, Jacob MC, Colomb MG: Measurement of anti-phospholipid antibodies by ELISA using β2-glycoprotein I as an antigen. J Immunol Methods 143: 223229, 1991
  • 41
    Viard J-P, Amoura Z, Bach J-F: Association of anti-β2-glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 93: 181186, 1992
  • 42
    Onyiriuka EC, Hersh IS, Herti W: Surface modification of polystyrene by gamma-radiation. Appl Spectrom 44: 808811, 1990
  • 43
    Cabiedes J, Cabral AR, Alarcón-Segovia D: Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-β2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 22: 18991906, 1995
  • 44
    Del Papa N, Guidali L, Spatola L, Bonara P, Borghi MO, Tincani A, Balestrieri G, Meroni PL: Relationship between antiphospholipid and anti-endothelial cell antibodies III: β2-glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol 13: 179185, 1995
  • 45
    Balestrieri G, Tincani A, Spatola L, Allegri F, Prati E, Cattaneo R, Valesini G, Del Papa N, Meroni P: Anti-beta2-glycoprotein I antibodies: a marker of antiphospholipid syndrome? Lupus 4: 122130, 1995
  • 46
    Martinuzzo ME, Forastiero RR, Carreras LO: Anti-β2-glycoprotein I antibodies: detection and association with thrombosis. Br J Haematol 89: 397402, 1995
  • 47
    Roubey RAS, Maldonado MA, Byrd SN: Comparison of an enzyme-linked immunosorbent assay for antibodies to β2-glycoprotein I and a conventional anticardiolipin immunoassay. Arthritis Rheum 39: 16061607, 1996
  • 48
    Pierangeli SS, Harris EN, Davis SA, DeLorenzo G: β2-glycoprotein I (β2GPI) enhances cardiolipin binding activity but is not the antigen for antiphospholipid antibodies. Br J Haematol 82: 565570, 1992
  • 49
    Triplett DA: Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res 78: 131, 1995
  • 50
    Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB: A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 61: 684692, 1983
  • 51
    Edson JR, Vogt JM, Hasegawa DK: Abnormal prothrombin crossed-immunoelectrophoresis in patients with lupus inhibitors. Blood 64: 807816, 1984
  • 52
    Fleck RA, Rapaport SI, Rao LV: Anti-prothrombin antibodies and the lupus anticoagulant. Bllod 72: 512519, 1988
  • 53
    Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA: Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 66: 629632, 1991
  • 54
    Permpikul P, Rao LVM, Rapaport SI: Functional and binding studies of the roles of prothrombin and β2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 83: 28782892, 1994
  • 55
    Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG: Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 74: 11201125, 1995
  • 56
    Galli M, Finazzi G, Bevers EM, Barbui T: Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and β2-glycoprotein I-dependent antiphospholipid antibodies. Blood 86: 617623, 1995
  • 57
    Oosting JD, Derksen RHWM, Entjes HTI, Bouma BN, De Groot PG: Lupus anticoagulant activity is frequently dependent on the presence of β2-glycoprotein I. Thromb Haemost 67: 499502, 1992
  • 58
    Arvieux J, Pouzol P, Roussel B, Jacob MC, Colomb MG: Lupus-like anticoagulant properties of murine monoclonal antibodies to β2-glycoprotein I. Br J Haematol 81: 568573, 1992
  • 59
    Kapur A, Kelsey PR, Isaacs PE: Factor V inhibitor in thrombosis. Am J Hematol 42: 384388, 1993
  • 60
    Koyama T, Saito T, Kusano T, Hirosawa S: Factor V inhibitor associated with Sjögren's syndrome. Br J Haematol 89: 893896, 1995
  • 61
    Pierangeli SS, Harris EN, Gharavi AE, Goldsmith G, Branch DW, Dean WL: Are immunoglobulins with lupus anticoagulant activity specific for phospholipids? Br J Haematol 85: 124132, 1993
  • 62
    Goldsmith GH, Pierangeli SS, Branch DW, Gharavi AE, Harris EN: Inhibition of prothrombin activation by antiphospholipid antibodies and β2-glycoprotein I. Br J Haematol 87: 548554, 1994
  • 63
    Rauch J, Tannenbaum M, Tannenbaum H, Ramelson H, Cullis PR, Tilcock CPS, Hope MJ, Janoff AS: Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J Biol Chem 261: 96729677, 1986
  • 64
    Esmon CT: The protein C anticoagulant pathway. Arterioscler Thromb Vasc Biol 12: 135145, 1992
  • 65
    Oosting JD, Preissner KT, Derksen RHWM, De Groot PG: Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro. Br J Haematol 85: 761768, 1993
  • 66
    Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, De Groot PG: Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 81: 26182625, 1993
  • 67
    Fillit H, Lahita R: Antibodies to vascular heparan sulfate proteoglycan in patients with systemic lupus erythematosus. Autoimmunity 9: 159164, 1991
  • 68
    Fillit H, Shibata S, Sasaki T, Speira H, Kerr LD, Blake M: Autoantibodies to the protein core of vascular basement membrane heparan sulfate proteoglycan in systemic lupus erythematosus. Autoimmunity 14: 243249, 1993
  • 69
    Shibata S, Harpel PC, Gharavi A, Rand J, Fillit H: Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 83: 25322540, 1994
  • 70
    Van Heerde WL, De Groot PG, Reutelingsperger CPM: The complexity of the phospholipid binding protein annexin V. Thromb Haemost 73: 172179, 1995
  • 71
    Matsuda J, Saitoh N, Gohchi K, Gotoh M, Tsukamoto M: Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol 47: 5658, 1994
  • 72
    Sammaritano LR, Gharavi AE, Soberano C, Levy RA, Lockshin MD: Phospholipid binding of antiphospholipid antibodies and placental anticoagulant protein. J Clin Immunol 12: 2735, 1992
  • 73
    Sugi T, McIntyre JA: Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 86: 30833089, 1995
  • 74
    Rock G, Chauhan K, Jamieson GA, Tandon NN: Anti-CD36 antibodies in patients with lupus anticoagulant and thrombotic complications. Br J Haematol 88: 878880, 1994
  • 75
    Schorer AE, Duane PG, Woods VL, Niewoehner DE: Some antiphospholipid antibodies inhibit phospholipase A2 activity. J Lab Clin Med 120: 6777, 1992
  • 76
    Vermylen J, Arnout J: Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes? J Lab Clin Med 120: 1012, 1992
  • 77
    Papo T, Piette J-C, Legao E, Frances C, Grenot P, Debre P, Godeau P, Autran B: T lymphocyte subsets in primary antiphospholipid syndrome. J Rheumatol 21: 22422245, 1994
  • 78
    Arnett FC, Olsen ML, Anderson KL, Reveille JD: Molecular analysis of major histocompatibility complex alleles associated with the lupus anticoagulant. J Clin Invest 87: 14901495, 1991
  • 79
    Loizou S, Cofiner C, Weetman AP, Walport MJ: Immunoglobulin class and IgG subclass distribution of anticardiolipin antibodies in patients with systemic lupus erythematosus and associated disorders. Clin Exp Immunol 90: 434439, 1992
  • 80
    Kita Y, Sumida T, Iwamoto I, Yoshida S, Koike T: V gene analysis of anti-cardiolipin antibodies from (NZW × BXSB) F1 mice. Immunology 82: 494501, 1994
  • 81
    Blank M, Krause I, Lanir N, Vardi P, Gilburd B, Tincani A, Tomer Y, Shoenfeld Y: Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation: the importance of the T cell. Arthritis Rheum 38: 115122, 1995
  • 82
    Tan EM: Autoantibodies in pathology and cell biology. Cell 67: 841842, 1991
  • 83
    Harris EN, Chan JKH, Asherson RA, Aber VA, Gharavi AE, Hughes GRV: Thrombosis, recurrent fetal loss, thrombocytopenia: predictive value of IgG anticardiolipin antibodies. Arch Intern Med 146: 21532156, 1986
  • 84
    Blank M, Cohen J, Toder V, Shoenfeld Y: Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A 88: 30693073, 1991
  • 85
    Branch DW, Dudley DJ, Mitchell MD: IgG fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 163: 210216, 1990
  • 86
    Pierangeli SS, Liu XW, Barker JH, Anderson G, Harris EN: Induction of thrombosis in a mouse model by IgG, IgM, and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 74: 13611367, 1995
  • 87
    Dahlbäck B: Physiological anticoagulation: resistance to activated protein C and venous thromboembolism. J Clin Invest 94: 923927, 1994
  • 88
    Sanson B-J, Friederich PW, Simioni P, Zanardi S, Huisman MV, Girolami A, ten Cate J-W, Prins MH: The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 75: 387388, 1996
  • 89
    Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein RL: Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 96: 22112219, 1995
  • 90
    Branch DW: Thoughts on the mechanism of pregnancy loss associated with the antiphospholipid syndrome. Lupus 3: 275280, 1994
  • 91
    De Wolf F, Carreras LO, Moerman P, Vermylen J, van Assche A, Renaer M: Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss and a lupus anticoagulant. Am J Obstet Gynecol 142: 829834, 1982
  • 92
    Rand JH, Wu XX, Guller S, Gil J, Guha A, Scher J, Lockwood CJ: Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 171: 15661572, 1994
  • 93
    McCrae KR, DeMichele AM, Pandhi P, Balsai MJ, Samuels P, Graham C, Lala PK, Cines DB: Detection of antitrophoblast antibodies in the sera of patients with anticardiolipin antibodies and fetal loss. Blood 82: 27302741, 1993
  • 94
    Sthoeger ZM, Mozes E, Tartakovsky B: Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc Natl Acad Sci U S A 90: 64646467, 1993
  • 95
    Shi W, Chong BH, Chesterman CN: β2-Glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood 81: 12551262, 1993
  • 96
    Arvieux J, Roussel B, Pouzol P, Colomb MG: Platelet activating properties of murine monoclonal antibodies to β2-glycoprotein I. Thromb Haemost 70: 336341, 1993
  • 97
    Peaceman AM, Silver RK, MacGregor SN, Socol ML: Interlaboratory variation in antiphospholipid antibody testing. Am J Obstet Gynecol 166: 17801787, 1992
  • 98
    Comp PC, DeBault LE, Esmon NL, Esmon CT: Human thrombomodulin is inhibited by IgG from two patients with non-specific anticoagulants (abstract). Blood 62 (Suppl 1): 299a, 1983
  • 99
    Cariou R, Tobelem G, Bellucci S, Soria J, Soria C, Maclouf J, Caen J: Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells—inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 60: 5458, 1988
  • 100
    Amer L, Kisiel W, Searles RP, Williams RC Jr: Impairment of the protein C anticoagulant pathway in a patient with systemic lupus erythematosus, anticardiolipin antibodies and thrombosis. Thromb Res 57: 247258, 1990
  • 101
    Marciniak E, Romond EH: Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 74: 24262432, 1989
  • 102
    Malia RG, Kitchen S, Greaves M, Preston FE: Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 76: 101107, 1990
  • 103
    Lo SC, Salem HH, Howard MA, Oldmeadow MJ, Firkin BG: Studies of natural anticoagulant proteins and anticardiolipin antibodies in patients with the lupus anticoagulant. Br J Haematoll 76: 380386, 1990
  • 104
    Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT: On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 95: 309316, 1995
  • 105
    Shibata S, Sasaki T, Harpel P, Fillit H: Autoantibodies to vascular heparan sulfate proteoglycan in systemic lupus erythematosus react with endothelial cells and inhibit the formation of thrombin-antithrombin III complexes. Clin Immunol Immunopathol 70: 114123, 1994
  • 106
    Francis RB Jr, McGehee WG, Feinstein DI: Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis. Thromb Haemost 59: 412414, 1988
  • 107
    Violi F, Ferro D, Valesini G, Quintarelli C, Saliola M, Grandilli MA, Balsano F: Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis. BMJ 300: 10991102, 1990
  • 108
    Sanfelippo MJ, Drayna CJ: Prekallikrein inhibition associated with the lupus anticoagulant: a mechanism of thrombosis. Am J Clin Pathol 77: 275279, 1982
  • 109
    Killeen AA, Meyer KC, Vogt JM, Edson JR: Kallikrein inhibition and C1-esterase inhibitor levels in patients with lupus inhibitor. Am J Clin Pathol 88: 223228, 1987
  • 110
    Tannenbaum SH, Finko R, Cines DB: Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol 137: 15321537, 1986
  • 111
    Oosting JD, Derksen RHWM, Blokzijl L, Sixma JJ, De Groot PG: Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity—studies in a thrombosis model. Thromb Haemost 68: 278284, 1992
  • 112
    Carreras LO, DeFreyn G, Machin SJ, Vermylen J, Deman R, Spitz B, van Assche A: Arterial thrombosis, intrauterine death and “lupus” anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet i: 244246, 1981
  • 113
    Maclouf J, Lellouche F, Martinuzzo M, Said P, Carreras LO: Increased production of platelet-derived thromboxane in patients with lupus anticoagulants. Agents Actions Suppl 37: 2733, 1992
  • 114
    Martinuzzo ME, Maclouf J, Carreras LO, Lévy-Toledano S: Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost 70: 667671, 1993
  • 115
    Silver RK, Adler L, Hickman AR, Hageman JR: Anticardiolipin antibody-positive serum enhances endothelial cell platelet-activating factor production. Am J Obstet Gynecol 165: 17481752, 1991
  • 116
    Ichikawa Y, Kobayashi N, Kawada T, Shimizu H, Moriuchi J, Ono H, Watanabe K, Arimori S: Reactivities of antiphospholipid antibodies to blood cells and their effects on platelet aggregations in vitro. Clin Exp Rheumatol 8: 461468, 1990